Recently added
This page was added on 29 June 2023.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Registered for use in infants and toddlers aged ≥6 weeks.
DT5aP-hepB-IPV-Hib(PRP-OMP) - (Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliovirus(inactivated), and Haemophilus influenzae type b conjugate vaccine.
The vaccine is a combination vaccine and consists of a monodose of 0.5 mL suspension in a pre-filled syringe.
The 0.5mL monodose suspension contains:
- ≥20 IU Diphtheria toxoid
- ≥40 IU Tetanus toxoid
- 20 µg Pertussis toxoid (PT)
- 20 µg Filamentous Haemagglutinin (FHA)
- 3 µg Pertactin (PRN)
- 5 µg Fimbriae types 2 and 3 (FIM)
- 10 µg Hepatitis B surface antigen (HBsAg)
- 40 D-antigen units Inactivated Poliovirus Type 1 (Mahoney)
- 8 D-antigen units Inactivated Poliovirus Type 2 (MEF-1)
- 32 D-antigen units Inactivated Poliovirus Type 3 (Saukett)
- 3 µg Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate)
- 50 µg Haemophilus influenzae type b polysaccharide (conjugated to meningococcal protein)
Also contains traces of:
- glutaraldehyde
- formaldehyde
- polymyxin B
- neomycin
- streptomycin
- bovine serum albumin
- dibasic and monobasic sodium phosphate
May contain yeast proteins.
For Product Information and Consumer Medicine Information about Vaxelis visit the Therapeutic Goods Administration website.
Vaxelis can be given at the same time as other scheduled vaccines, including MenB vaccines.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.